LifeArc’s Post

When we think of developing new medicines, we often imagine long, expensive research processes. But what if we could find new treatments by looking at the medicines we already have? This is the idea behind drug repurposing—taking drugs that are already approved for one condition and studying them to see if they can be used to treat other diseases. Today, I’m excited to be part of announcing a new clinical trial that will explore whether existing drugs can be repurposed to treat bronchiectasis  - a “hidden” lung condition affecting over 200,000 people in the UK.  If successful, this trial could fast-track new treatments where there is currently no specific one, offering hope to many people in the UK and beyond. #ClinicalTrial #MedicalInnovation #LungHealth #NewTreatments #ResearchForACure

JUST OUT, 🇯🇵 Japan’s Ministry of Health, Labour and Welfare granted approval for zolbetuximab, an innovative CLDN18.2 monoclonal antibody, marking a groundbreaking advancement in the treatment landscape for patients with CLDN18.2 positive, unresectable, advanced, or recurrent gastric cancer. This approval represents a significant milestone as zolbetuximab becomes the world's first and only CLDN18.2-targeted therapy sanctioned by a regulatory agency. The decision follows promising results from the Phase 3 SPOTLIGHT and GLOW clinical trials, which demonstrated substantial improvements in both progression-free survival (PFS) and overall survival (OS) among patients treated with zolbetuximab in combination with chemotherapy compared to those receiving placebo plus chemotherapy. https://lnkd.in/d6f6-z4t

#immunotherapies like #Imfinzi have set a new global standard for treating advanced biliary tract cancer by improving survival rates. The combination of Imfinzi with chemotherapy has shown promising three-year survival data in the TOPAZ-1 study, reducing mortality risk by 26%. Despite these groundbreaking results, the treatment remains uncovered by insurance in Korea, limiting access for patients. In this interview, Professor Oh Do-youn of Seoul National University Hospital discusses the significance of these findings and the challenges faced by Korean patients. https://lnkd.in/g9Esz8bd 

👏 ARENSIA has made a pivotal contribution to expediting the completion of a Phase IB trial involving patients with Idiopathic Pulmonary Fibrosis (IPF)! Our participation in a Phase IB study provided IPF patients with access to a novel therapeutic approach using a recombinant, humanized, full-length IgG4 monoclonal antibody. This Single Ascending Dose (SAD) study featured a highly sophisticated design, particularly concerning the required pulmonary assessments. We shared more interesting details about the study in the article below 👇👇👇 #IPF #IdiopathicPulmonaryFibrosis #clinicalresearch #clinicaltrials #earlyphase

Great work from the team at ARENSIA Exploratory Medicine GmbH for patients with IPF. Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by fibrosis of the lung tissue, leading to severe respiratory issues. Conducting early-phase clinical trials for IPF presents several unique challenges due to the nature of the disease and its patient population. Here are some of the key challenges: 1. Patient Recruitment and Enrollment: Rarity of the Disease: IPF is relatively rare, which limits the pool of potential participants. Finding enough eligible patients to enroll in trials can be difficult. Disease Progression Variability: The progression of IPF varies significantly among patients, making it challenging to standardize inclusion criteria and ensure a homogenous study population. Eligibility Criteria: Patients often have comorbid conditions or may be taking other medications that can exclude them from participation. If you would like to learn more regarding ARENSIA Exploratory Medicine GmbH clinics and trial feasibility in US, Moldova, Georgia, Romania, Bulgaria, Ukraine about IPF or any other indication drop me a line and I would be more than happy to help. #arensia #earlyphasetrials #patientrecruitment #adaptiveclinicaltrials

The comprehensive pharmacovigilance study extracted data from VigiBase, encompassing irAEs induced by immune-checkpoint inhibitors (ICI) reported from 2008 to 2023. Analyzing 50,347 cases, predominantly involving anti-PD1 monotherapy, the study revealed shifting prescription patterns favoring anti-PDL1 and combination therapies post-2020, with expanded usage across various cancer types. Skin reactions, pneumonitis, enterocolitis, and thyroiditis were the most common irAEs, while ICI-myotoxicities exhibited significant overlap and higher fatality rates, especially pre-2020. Noteworthy risk factors associated with specific irAEs include cancer type, ICI regimen, and regional variations. The study underscores the evolving landscape of irAEs, offering insights to inform clinical practice and future research directions. https://lnkd.in/dAY_37vC Source eClinicalMedicine Paul Gougis Floriane JOCHUM Bénédicte Lebrun-Vignes John Haanen Benedikt Westphalen Allison Betof Warner

Journal of Chemotherapy – Anticancer Drugs Section - Call for manuscripts - Reminder   Dear Colleagues,   As the Editor in Chief of Journal of Chemotherapy (JOC) for the Section of Anticancer Drugs, I renew to you my invitation to submit a review or research manuscript of yours to our Journal for Open Access (OA) publishing.   JOC OA publishing will fit your needs and amplify the visibility of your research on cancer therapeutics and predictive biomarkers.   As you might know, Journal of Chemotherapy is a peer-reviewed Journal with a long standing commitment to publish high-quality, innovative research focused on preclinical, translational and clinical aspects of all types of cancer drug therapies and on pharmacological as well as tumor biomarkers. It is covered by the most relevant bibliographic databases and repositories.    Publish with us and contribute to build a higher impact Journal together with other distinguished scientists from all World countries!   More information is available at: https://lnkd.in/dtPGeZkD   The JOC Anticancer Drugs Section has also recently launched two Special Collections of OA articles, one on "Protein Kinase Inhibitors for Targeted Cancer Therapy" (https://lnkd.in/dWBAS6vp) and one on "Cancer Immunotherapy" (https://lnkd.in/e3Je6Txm).   I thank you very much for your consideration and look forward to receiving your feedback soon.   If you are interested, you may find information on benefits of OA publishing with JOC at: https://lnkd.in/dj2fwGDn     Best regards,   Enrico Mini   Enrico Mini M.D., Ph.D. Editor-in-Chief Anticancer Drugs Section Journal of Chemotherapy #Anticancerdrugs #Cancerimmunotherapy #CancerRNAtherapeutics #Cancergenetherapy #Anticancerdrugdiscovery #Anticancerdrugdevelopment #Preclinicalcancerpharmacology #Anticancerdrugresistance #Translationalcancerpharmacology #Clinicalcancerpharmacology #Clinicaltrials #Realworlddrugstudies #Pharmacologicalbiomarkers #Tumorbiomarkers #Precisionmedicineincancertherapy #Anticancerdrugadverseevents #Anticancerdrugpharmacoeconomics

#ClinicalMonday FDA Grants Accelerated Approval to Lifileucel for Advanced Melanoma 🚀 The FDA has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics) for adults with unresectable or metastatic melanoma who have exhausted other treatment options. This new therapy has shown a 31.5% objective response rate in clinical trials, offering new hope to patients facing this challenging disease. 🔐 Key Highlights: 🔑 New Option Approved for patients previously treated with a PD-1 blocking antibody and BRAF/MEK inhibitors. 🔑 Efficacy Demonstrated a 31.5% response rate in trials. 🔑 Complex Regimen Involves chemotherapy, T cell infusion, and IL-2 support. 🔑 Boxed Warning Lifileucel has a Boxed Warning for treatment-related mortality and serious adverse reactions, including severe cytopenia, severe infection, and cardiopulmonary and renal impairment. 🔑 Adverse Reactions Monitoring Common adverse reactions (≥20%) include chills, fever, fatigue, rapid heartbeat, diarrhea, febrile neutropenia, swelling, rash, low blood pressure, hair loss, infection, low oxygen levels, and difficulty breathing. This approval underscores the importance of innovative treatments in the fight against cancer, providing new avenues for those in critical need. 🌟 📚 Find out more details here: https://lnkd.in/g5KP48F4 #CancerResearch #Melanoma #FDAApproval #Immunotherapy #HealthcareInnovation #Biotech Image source: Yaofenxiang

Less frequent dosing of #osimertinib may be a valid treatment option, especially in the second line and beyond setting in patients who cannot afford full dose daily osimertinib. This may provide an additional treatment option with a similar toxicity profile as that of standard dose osimertinib. It seems mostly for oncology for Indian patients works at low dose or at intermettint dose. Does this open up need for dose modified CT (RWE) in India for popular regime and drugs and modified packaging 😇 No wonder #AstraZeneca priced 40mg osimertinib at par with 80mg, not giving opportunity for down titration ( Patient Centricity at its Peak)

🔦 This is a significant advancement in melanoma treatment, offering hope to those with limited options. The accelerated approval of lifileucel highlights the potential of innovative therapies in combating challenging diseases.  ✍ Find out more about a promising new therapy and the critical safety measures that accompany it in the latest #ClinicalMonday review by The Babak Lab #FDAApprocal #CancerResearch #MedicalInnovation #Healthcare